GC
TVTX icon

Guggenheim Capital’s Travere Therapeutics TVTX Stock Holding History

Guggenheim Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.15M Sell
37,877
-8,241
-18% -$365K 0.01% 710
2026
Q1 		$1.37M Buy
46,118
+8,915
+24% +$267K 0.01% 856
2025
Q4 		$1.42M Buy
37,203
+27,901
+300% +$907K 0.01% 781
2025
Q3 		$222K Buy
+9,302
New +$175K ﹤0.01% 1491

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Guggenheim Capital's TVTX Position: Q2 2026 in Review

Guggenheim Capital reduced its Travere Therapeutics (TVTX) stake by 18% in Q2 2026, selling an estimated $365K and leaving 37,877 shares worth $2.15M. The position accounts for 0.01% of the portfolio, ranked #710.

Guggenheim Capital first reported a position in TVTX in Q3 2025 and has held it in 4 quarters since. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Guggenheim Capital held 37,877 shares of Travere Therapeutics worth $2.15M as of Q2 2026.
  • Guggenheim Capital sold 8,241 Travere Therapeutics shares in Q2 2026, an estimated $365K.
  • Travere Therapeutics made up 0.01% of Guggenheim Capital's portfolio in Q2 2026, its #710 holding.
  • Guggenheim Capital first reported a position in Travere Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.